Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 8th Annual MASH Virtual Conference. The company's Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will take part in a fireside chat during the event.
The presentation is scheduled for Monday, October 7, 2024, at 11:30 a.m. EDT. Interested parties can access the webcast of the session by visiting the Events section of the Altimmune website. This participation provides an opportunity for the company to share insights and updates with investors and industry professionals in a virtual setting.
Altimmune, Inc. (Nasdaq: ALT), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 8ª Conferenza Virtuale MASH Annuale di H.C. Wainwright. Il Chief Executive Officer, Vipin Garg, Ph.D., e il Chief Medical Officer, Scott Harris, M.D., parteciperanno a una chiacchierata informale durante l'evento.
La presentazione è programmata per lunedì 7 ottobre 2024, alle 11:30 EDT. Le parti interessate possono accedere alla trasmissione web della sessione visitando la sezione Eventi del sito web di Altimmune. Questa partecipazione offre un'opportunità per l'azienda di condividere intuizioni e aggiornamenti con investitori e professionisti del settore in un contesto virtuale.
Altimmune, Inc. (Nasdaq: ALT), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la octava Conferencia Virtual Anual MASH de H.C. Wainwright. El Consejero Delegado, Vipin Garg, Ph.D., y el Director Médico, Scott Harris, M.D., participarán en una conversación informal durante el evento.
La presentación está programada para el lunes 7 de octubre de 2024, a las 11:30 a.m. EDT. Las partes interesadas pueden acceder a la transmisión web de la sesión visitando la sección de Eventos del sitio web de Altimmune. Esta participación brinda la oportunidad a la empresa de compartir perspectivas y actualizaciones con inversores y profesionales de la industria en un formato virtual.
Altimmune, Inc. (Nasdaq: ALT), 임상 단계의 생명공학 회사는 H.C. Wainwright 제8회 연례 MASH 온라인 컨퍼런스 참여를 발표했습니다. 회사의 CEO Vipin Garg, Ph.D. 및 CMO Scott Harris, M.D.가 이벤트 중 파이어사이드 챗에 참여할 것입니다.
발표는 2024년 10월 7일 월요일 오전 11:30 EDT로 예정되어 있습니다. 관심 있는 사람들은 Altimmune 웹사이트의 행사 섹션을 방문하여 세션의 웹캐스트에 접근할 수 있습니다. 이번 참여는 회사가 투자자 및 업계 전문가들과 가상 환경에서 통찰과 업데이트를 공유할 수 있는 기회를 제공합니다.
Altimmune, Inc. (Nasdaq: ALT), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 8ème Conférence Virtuelle Annuelle MASH de H.C. Wainwright. Le Directeur Général, Vipin Garg, Ph.D., et le Directeur Médical, Scott Harris, M.D., participeront à une discussion informelle durant l'événement.
La présentation est prévue pour le lundi 7 octobre 2024 à 11h30 EDT. Les parties intéressées peuvent accéder à la rediffusion de la session en visitant la section Événements du site web d'Altimmune. Cette participation offre à l'entreprise l'opportunité de partager des insights et des mises à jour avec des investisseurs et des professionnels de l'industrie dans un format virtuel.
Altimmune, Inc. (Nasdaq: ALT), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seine Teilnahme an der 8. jährlichen MASH-Virtual-Konferenz von H.C. Wainwright bekannt gegeben. Der CEO, Vipin Garg, Ph.D., und der Chief Medical Officer, Scott Harris, M.D., werden während der Veranstaltung an einem fireside chat teilnehmen.
Die Präsentation ist für Montag, den 7. Oktober 2024, um 11:30 Uhr EDT geplant. Interessierte Parteien können die Übertragung der Sitzung im Bereich Veranstaltungen der Altimmune-Website ansehen. Diese Teilnahme bietet dem Unternehmen die Möglichkeit, Einblicke und Updates mit Investoren und Branchenprofis in einer virtuellen Umgebung zu teilen.
- None.
- None.
GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference:
| Conference: | H.C. Wainwright 8thAnnual MASH Virtual Conference |
| Presenters: | Vipin Garg, Ph.D., Chief Executive Officer |
| Scott Harris, M.D., Chief Medical Officer | |
| Date/Time: | Monday, October 7, 2024, at 11:30 a.m. EDT |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) participating in the H.C. Wainwright MASH Virtual Conference?
Who will represent Altimmune (ALT) at the H.C. Wainwright conference?
How can investors access Altimmune's (ALT) presentation at the H.C. Wainwright conference?
What type of session will Altimmune (ALT) participate in at the H.C. Wainwright conference?
